25th Jun 2025 07:00
MaxCyte Inc.
("MaxCyte" or the "Company")
Last Day of Dealings on AIM
ROCKVILLE, Md., LONDON, UK., 25 June, 2025 MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics today provides a further update with regards to the cancellation of admission of the Company's common stock ("Common Stock") to trading on AIM (the "Cancellation"), as approved by shareholders at the Annual General Meeting held on 18 June 2025.
Shareholders are reminded that the last day of dealings in the Company's Common Stock on AIM will be 25 June 2025 and that the cancellation of their admission to trading on AIM will take place at 7:00 a.m. (UK time) on 26 June 2025.
Following the delisting, there will be no public market in the United Kingdom on which the Common Stock can be traded, however the Company will retain its U.S. listing of Common Stock on the Nasdaq Global Select Market ("Nasdaq") under ticker symbol MXCT.
Further information regarding the delisting can be found at: https://investors.maxcyte.com/static-files/529f4a8b-c6e9-4db6-bfc1-6a2da9f0252a.
For further information, please contact:
MaxCyte Contacts: US IR Adviser Gilmartin Group David Deuchler, CFA
|
+1 415-937-5400
| ||
Nominated Adviser and Joint Corporate Broker Panmure Liberum Emma Earl / Mark Rogers Corporate Broking Rupert Dearden |
+44 (0)20 7886 2500 | ||
UK IR Adviser ICR Healthcare Mary-Jane Elliott Chris Welsh |
+44 (0)203 709 5700
|
About MaxCyte
At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine. Learn more at maxcyte.com and follow us on X and LinkedIn.
Related Shares:
MaxCyte